Silvaco to Accelerate Physics-Based Digital Twins for Semiconductor Design and Manufacturing Using NVIDIA AI and Accelerated Computing 
ATAL Wins the Theme Award of BDO ESG Awards 
NICE Marketing Corp Expands Global Reach Through Innovative Digital Music Marketing Solutions U.S. Polo Assn. Launches Global Fall-Winter 2023 Collection
WEST PALM BEACH, FL / ACN Newswire / September 26, 2023 / U.S. Polo Assn.,…
New Relic Launches Session Replay
Video-like playback feature includes privacy controls like encryption and obfuscation SAN FRANCISCO–(BUSINESS WIRE)–#newrelic—New Relic (NYSE:…
Qumulo Expands Strategic Relationship with Fujitsu to Help EMEA Customers Scale Anywhere
Fujitsu’s PRIMERGY M7 Platform Now Certified by Qumulo, Provides Companies with More Options to Cost…
Utilities Tackle Disruptions With Asset Management Tools
Aging power grids, green energy expansion and growing risks make knowledge and control of plants…
Evaggelia Hatzimanolis Joins Lido as a Senior Wealth Advisor
LOS ANGELES–(BUSINESS WIRE)–Lido Advisors, LLC (“Lido”) is proud to announce that Evaggelia Hatzimanolis has joined…
Immersive Labs Unveils Enterprise-Class Cyber Skills and Resilience Platform for the Entire Organization
New ‘Workforce Exercising’ Solution Extends the Immersive Labs Platform to Allow Leaders to Build and…
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those…
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those…
Cabiri unveils Launch, a packaged composable commerce solution for fast-growing enterprises
LONDON, Sept. 26, 2023 (GLOBE NEWSWIRE) — Today, Cabiri, a boutique systems integrator renowned for…
One Page Case Studies Announces Report on Success Story Writing for Landscapers
Success story content marketing specialist One Page Case Studies announces a new report analyzing how…
Overview of Honda Exhibits at the JAPAN MOBILITY SHOW 2023
TOKYO, Sep 26, 2023 – (JCN Newswire) – Honda booth image*Note: Vehicles/exhibits shown in these…
Zayo Supercharges Connectivity With Fully-Enabled 400G European Network
Enhanced network expands capacity and scalability to support global bandwidth demands BOULDER, Colo.–(BUSINESS WIRE)–Zayo Group,…
Nardello & Co. Continues Global Expansion with New Leadership in EMEA
LONDON & DUBAI, United Arab Emirates & NEW YORK–(BUSINESS WIRE)–Nardello & Co., the global investigations…
OpenX Announces ConteX, the Next Generation of Contextual Solutions for Brands and Agencies to Target Ad Campaigns Safely, Effectively, and at Scale
ConteX represents the future of contextual buying by delivering effective targeting, contract-free activation, and broader…
OpenX Announces ConteX, the Next Generation of Contextual Solutions for Brands and Agencies to Target Ad Campaigns Safely, Effectively, and at Scale
ConteX represents the future of contextual buying by delivering effective targeting, contract-free activation, and broader…
OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board
PRESS RELEASE OMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory Board Oxford, United Kingdom…
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11…
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
If approved, Dupixent would be the first and only treatment in the U.S. indicated for…
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to…
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26…